Abstracts tagged "DMARDs"

Abstract Number: 688 • 2018 ACR/ARHP Annual Meeting
Real Life Analysis of a Latin America Tertiary Spondyloarthritis Single-Center: High Frequency of Peripheral Involvement and Use of Synthetic Dmard
Andrea Shimabuco¹, Julio CB Moraes¹, Percival Sampaio-Barros², Cláudia Goldenstein-Schainberg¹, Celio R. Gonçalves¹, Ana CM Ribeiro¹ and Carla GS Saad¹, ¹Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil
Background/Purpose: The use of synthetic DMARDS (sDMARDs) in spondyloarthritis (SpA) has been increasingly questioned and restricted to peripheral disease, on the other hand, the use…
Abstract Number: 1541 • 2018 ACR/ARHP Annual Meeting
The Safety Profile of Iguratimod in Real Clinical Practice: Analysis of 491 Patients with Rheumatoid Arthritis
Yukihiko Ikeda¹, Ryo Rokutanda¹, Sho Fukui¹, Haruki Sawada², Mitsuru Watanabe³, Ayako Koido³, Yuko Kataoka¹, Rui Kawato⁴, Haruyuki Yanaoka⁵, Masei Suda⁶, Yuri Ohara⁷, Hiromichi Tamaki¹, Hisanori Shimizu⁶, Tokutaro Tsuda¹, Ken-ichi Yamaguchi⁸, Mitsumasa Kishimoto¹ and Masato Okada¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Immune-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Immuno rheumatology center, St. Luke's International Hospital, Tokyo, Japan, ⁵St. Luke's International Hospital, Tokyo, Japan, ⁶Immuno-Rheumatology Center, St luke's International hospital, Tokyo, Japan, ⁷Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁸Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan
The retention rate and safty profile of iguratimod in real clinical practice: Analysis of 456 patients with Rheumatoid arthritis. Abstract Background/Purpose: Iguratimod is one of…
Abstract Number: 2466 • 2018 ACR/ARHP Annual Meeting
Prolonged Delay in Presentation to Rheumatologists for Hispanic Patients with Rheumatoid Arthritis Contributes to Later Diagnosis and Treatment
Mariam Riad¹, Daniel Dunham², Jacquelin R. Chua¹, Theodore Pincus¹, Najia Shakoor¹, Sobia Hassan¹, Joel A. Block¹ and Isabel Castrejón¹, ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Division of Internal Medicine, Rush University Medical Center, Chicago, IL
Background/Purpose: Disparities in the initiation of disease modifying anti-rheumatic drugs (DMARDs) in ethnic minorities have been described in rheumatoid arthritis (RA) patients in the US…
Abstract Number: 305 • 2018 ACR/ARHP Annual Meeting
Introduction and Value of a Shortened Psamris-7 in Psa-Patients before and after Treatment Escalation to Bdmard Using High Resolution MRI
Philipp Sewerin¹, Daniel Benjamin Abrar², Christine Goertz³, Marco Jung⁴, Matthias Schneider⁵, Benedikt Ostendorf¹ and Christoph Schleich⁶, ¹Department and Hiller-Research-Unit for Rheumatology, Heinrich-Heine University, Düsseldorf, Germany, ²Department for diagnostic and interventional Radiology, Heinrich-Heine-Universitiy, Duesseldorf, Germany, ³Department and Hiller-Research-Unit for Rheumatology, Heinrich-Heine-Universitiy, Duesseldorf, Germany, ⁴Department and Hiller-Research-Unit for Rheumatologie, Heinrich-Heine Universitiy, Duesseldorf, Germany, ⁵Department and Hiller-Research-Unit for Rheumatology, Heinrich-Heine University, Duesseldorf, Germany, ⁶Department for diagnostic and interventional Radiology, Heinrich-Heine University, Duesseldorf, Germany
Background/Purpose: The aim of the study was to evaluate a simplified version of the OMERACT Psoriasis Arthritis Magnetic Resonance Imaging Score (PsAMRIS) to seven regions…
Abstract Number: 697 • 2018 ACR/ARHP Annual Meeting
Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit
Clara Pérez-Velásquez¹, Maria Luz Garcia Vivar², Silvia Perez Barrio³, Eva Galindez-Agirregoikoa¹, Esther Ruíz Lucea¹, Ignacio Torre-Salaberri⁴, Olaia Fernández-Berrizbeitia¹, Ana Rosa Inchaurbe Pellejero², Juan Blanco Madrigal¹, Edurne Guerrero Basterretxea², Itziar Calvo Zorrilla², Oihane Ibarguengoitia², David Montero², Natalia Rivera-García¹, Maria Jesus Allande Lopez Linares¹ and Iñigo Gorostiza-Hormaetxe⁵, ¹Rheumatology, University Hospital of Basurto, Bilbao, Spain, ²Rheumatology, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Dermatology, University Hospital of Basurto, Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ⁵Unit of Research, University Hospital of Basurto, Bilbao, Spain
Background/Purpose: We consider multidisciplinary management necessary, especially in a subgroup of patients with Psoriatic Arthritis (PsA) for complexity, cutaneous and / or joint involvement. Despite…
Abstract Number: 1542 • 2018 ACR/ARHP Annual Meeting
Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Joel Kremer¹, Laura C. Cappelli², Carol J. Etzel³, Jeffrey Greenberg³, Jamie Geier⁴, Ann Madsen⁴, Connie Chen⁴, Alina Onofrei³, Christine J Barr³, Dimitrios A. Pappas³, Kimberly J Dandreo³, Andrea Shapiro⁵, Carol A Connell⁶ and Arthur Kavanaugh⁷, ¹Albany Medical College and the Center for Rheumatology, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona LLC, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Peapack, NJ, ⁶Pfizer Inc, Groton, CT, ⁷University of California, San Diego School of Medicine, La Jolla, San Diego, CA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A prospective observational 5-year study, embedded within the US Corrona RA registry,…
Abstract Number: 2468 • 2018 ACR/ARHP Annual Meeting
Window or No Window? Earlier Is Better When Treating Rheumatoid Arthritis
Sytske Anne Bergstra¹, Joy A. van der Pol², Nagmeh Riyazi³, Yvonne P. Goekoop-Ruiterman³, Arvind Chopra⁴, José António P. da Silva⁵, Pit J.S.M. Kerstens⁶, Willem F. Lems⁷, S. Tsonaka⁸, Tom W.J. Huizinga¹ and Cornelia F. Allaart¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³HAGA Hospital, The Hague, Netherlands, ⁴Center for Rheumatic Diseases, Pune, India, ⁵Department of rheumatology, Centro Hospitalar e Universitário de Coimbra (SRHUC), Coimbra, Portugal, ⁶Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ⁷Department of Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁸Department of Medical Statistics and Bioinformatics, LUMC, Leiden, Netherlands
Background/Purpose: Previous reports on a window of opportunity (WOO) in rheumatoid arthritis (RA) may be related to the use of slow acting csDMARDs. We investigated…
Abstract Number: 496 • 2018 ACR/ARHP Annual Meeting
Heart Failure Risk Among Patients with Rheumatoid Arthritis: Association with Anti-Rheumatic Drugs
Michael Ahlers¹, C. Michael Stein², Cecilia P. Chung², Michelle J. Ormseth³, Eric Farber-Eger³ and Deepak Gupta⁴, ¹4906 illinois avenue, Vanderbilt University School of Medicine, Nashville, TN, ²Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Internal Medicine - Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of coronary artery disease (CAD), but the association with heart failure (HF) is less characterized. We…
Abstract Number: 887 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards
Yoshiya Tanaka¹, Tsutomu Takeuchi², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Yeong Wook Song⁶, Yi-Hsing Chen⁷, Mitsuhiro Rokuda⁸, Hiroyuki Izutsu⁸, Satoshi Ushijima⁸, Yuichiro Kaneko⁸, Teruaki Shiomi⁸ and Emi Yamada⁸, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁷Taichung Veterans General Hospital, Taichung City, Taiwan, ⁸Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate to severe RA in a phase 2b study…
Abstract Number: 1659 • 2018 ACR/ARHP Annual Meeting
Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results
Roy Fleischmann¹, Vinod Chandran², Eric Lespessailles³, Julie Birt⁴, Olivier Benichou⁴, Janelle Erickson⁴ and Catherine Shuler⁴, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Krembil Research Institute and University of Toronto, Toronto, ON, Canada, ³University of Orléans, Orléans, France, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements compared to placebo not only in disease activity but also in various…
Abstract Number: 2500 • 2018 ACR/ARHP Annual Meeting
Association between Anti-Citrullinated Protein Antibody Status, Erosive Disease and Healthcare Resource Utilization in Patients with RA
Leslie R Harrold¹, Lin Guo², Sean E. Connolly³, Evo Alemao³, Sabrina Rebello⁴, Ying Shan⁴ and Joel Kremer⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Waltham, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Anti-citrullinated protein antibody (ACPA) is a highly specific biomarker for RA1 and ACPA-seropositive patients have a tendency toward severe erosive disease and more rapid…
Abstract Number: 543 • 2018 ACR/ARHP Annual Meeting
Disease Severity Among Bio-Naive RA Patients on Csdmards
Leslie R. Harrold^1,2, Jenny Griffith³, Heather J Litman⁴, Hua Feng², Casey A. Schlacher⁵ and Joel Kremer⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Waltham, MA, ³AbbVie, Inc., North Chicago, IL, ⁴Corrona LLC, Waltham, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) are recommended as the first-line treatment for patients with rheumatoid arthritis (RA). Guidelines recommend escalation of treatment to…
Abstract Number: 940 • 2018 ACR/ARHP Annual Meeting
Inactivated Influenza Vaccine Prevents Respiratory Infections and Improves All-Cause and Cause-Specific Mortality in Immunosuppressed People with Autoimmune Rheumatic Diseases: Propensity Score Adjusted Cohort Study Using Data from Clinical Practice Research Datalink
Georgina Nakafero¹, Matthew Grainge², Puja Myles², Christian Mallen³, Weiya Zhang¹, Michael Doherty⁴, Jonathan Nguyen-van-tam² and Abhishek Abhishek¹, ¹Academic Rheumatology, The University of Nottingham, Nottingham, United Kingdom, ²Epidemiology and Public Health, The University of Nottingham, Nottingham, United Kingdom, ³Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ⁴The University of Nottingham, Nottingham, United Kingdom
Background/Purpose: To assess the effectiveness of inactivated influenza vaccine (IIV) in preventing influenza like illness (ILI), lower respiratory tract infection (LRTI), pneumonia, chronic obstructive pulmonary…
Abstract Number: 1697 • 2018 ACR/ARHP Annual Meeting
Refractory Lupus Patients: How Frequent Do We See Them in the 21st Century?
Valeria Scaglioni¹, Marina Scolnik¹, Enrique R Soriano¹ and Guillermo J. Pons-Estel², ¹Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina
Background/Purpose: management of systemic lupus erythematosus (SLE) patients is challenging because of the heterogeneity of the disease. While treatment of renal nephritis is more standardized,…
Abstract Number: 2523 • 2018 ACR/ARHP Annual Meeting
Rapid Response with Upadacitinib Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Csdmards or Bdmards
Oliver FitzGerald¹, Andrea Rubbert-Roth², Kun Chen³, Sebastian Meerwein⁴, Jose Jeffrey Enejosa³, Tim Shaw³ and Alvin F. Wells⁵, ¹St. Vincent’s Univ Hospital and Conway Inst Univ College Dublin, Dublin, Ireland, ²Kantonsspital St. Gallen, St Gallen, Switzerland, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Deutschland, Ludwigshafen, Germany, ⁵Rheum and Immunotherapy Ctr, Franklin, WI
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients (pts) with moderate to severe rheumatoid arthritis (RA) with an inadequate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].